AzurRx BioPharma, Inc. Contracts & Agreements
125 Contracts & Agreements
- Business Finance (88 contracts)
- Business Operations (8)
- Human Resources (8)
- Intellectual Property (3)
- Mergers & Acquisitions (2)
- Uncategorized (16)
- Consulting Agreement, dated August 2, 2024, by and between the Company and James Sapirstein (Filed With SEC on August 7, 2024)
- Form of Inducement Warrant (Filed With SEC on July 11, 2024)
- Form of Inducement Letter (Filed With SEC on July 11, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on May 13, 2024)
- Form of Common Warrant (Filed With SEC on May 13, 2024)
- Form of Placement Agency Agreement (Filed With SEC on May 13, 2024)
- Form of Purchase Agreement (Filed With SEC on May 13, 2024)
- Description of Capital Stock (Filed With SEC on March 29, 2024)
- Form of Purchase Agreement (Filed With SEC on March 29, 2024)
- Agreement and Plan of Merger, dated March 13, 2024, by and among First Wave BioPharma, Inc. IMMUNO Merger Sub I, Inc., IMMUNO Merger Sub II, LLC, and ImmunogenX, Inc (Filed With SEC on March 14, 2024)
- Form of Assumed Warrant (Filed With SEC on March 14, 2024)
- Amended Credit Agreement, dated as of October 3, 2022 and amended on September 6, 2023 and March 13, 2024, by and between the Company and Mattress Liquidators, Inc (Filed With SEC on March 14, 2024)
- Second Amended and Restated Revolving Loan Promissory Note, dated March 13, 2024 (Filed With SEC on March 14, 2024)
- Security Agreement, dated as of October 3, 2022, by and between ImmunogenX and Mattress Liquidators, Inc (Filed With SEC on March 14, 2024)
- Lender Support Letter, dated as of March 13, 2024, by and between ImmunogenX and Mattress Liquidators, Inc (Filed With SEC on March 14, 2024)
- Form of Shareholder Note (Filed With SEC on March 14, 2024)
- Form of Shareholder Security Agreement (Filed With SEC on March 14, 2024)
- Offer Letter, dated as of March 13, 2024, by and between Dr. Syage and the Company (Filed With SEC on March 14, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on March 5, 2024)
- Form of Common Warrant (Filed With SEC on March 5, 2024)
- Form of Placement Agency Agreement (Filed With SEC on March 5, 2024)
- Form of Purchase Agreement (Filed With SEC on March 5, 2024)
- Form of Inducement Warrant (Filed With SEC on December 27, 2023)
- Form of Inducement Letter (Filed With SEC on December 27, 2023)
- Form of Warrant Agency Agreement (Filed With SEC on December 27, 2023)
- Form of Placement Agency Agreement (Filed With SEC on December 18, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on December 18, 2023)
- Form of Common Warrant (Filed With SEC on December 18, 2023)
- Form of Warrant Agency Agreement (Filed With SEC on December 18, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on December 18, 2023)
- License Agreement, dated September 13, 2023 (Filed With SEC on October 10, 2023)
- Form of Inducement Warrant (Filed With SEC on September 15, 2023)
- Form of Inducement Letter (Filed With SEC on September 15, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on July 21, 2023)
- Form of Warrant (Filed With SEC on July 21, 2023)
- Form of Placement Agency Agreement (Filed With SEC on July 21, 2023)
- Form of Purchase Agreement (Filed With SEC on July 21, 2023)
- Form of Placement Agency Agreement (Filed With SEC on July 7, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on July 7, 2023)
- Form of Common Warrant (Filed With SEC on July 7, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on July 7, 2023)
- Amendment to the 2020 Omnibus Equity Incentive Plan (Filed With SEC on June 23, 2023)
- Form of Inducement Warrant (Filed With SEC on June 16, 2023)
- Form of Inducement Letter (Filed With SEC on June 16, 2023)
- Description of Capital Stock (Filed With SEC on March 20, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on March 15, 2023)
- Form of Warrant (Filed With SEC on March 15, 2023)
- Form of Purchase Agreement (Filed With SEC on March 15, 2023)
- Form of Registration Rights Agreement (Filed With SEC on March 15, 2023)
- Form of Settlement Agreement, by and between the Representative and the Company, dated November 30, 2022 (Filed With SEC on December 2, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on November 22, 2022)
- Form of Warrant (Filed With SEC on November 22, 2022)
- Form of Warrant Amendment Agreement (Filed With SEC on November 22, 2022)
- Form of Purchase Agreement (Filed With SEC on November 22, 2022)
- Form of Registration Rights Agreement (Filed With SEC on November 22, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on October 12, 2022)
- Form of Warrant (Filed With SEC on October 12, 2022)
- Form of Purchase Agreement (Filed With SEC on October 12, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on September 22, 2022)
- Form of Common Warrant (Filed With SEC on September 22, 2022)
- Form of Placement Agent Warrant (Filed With SEC on September 22, 2022)
- Form of Securities Purchase Agreement (Filed With SEC on September 22, 2022)
- Form of Term Sheet, by and between the Representative and the Company, dated July 29, 2022 (Filed With SEC on July 29, 2022)
- Form of Warrant (Filed With SEC on July 18, 2022)
- Form of Placement Agent Warrant (Filed With SEC on July 18, 2022)
- Form of Purchase Agreement (Filed With SEC on July 18, 2022)
- Form of Registration Rights Agreement (Filed With SEC on July 18, 2022)
- Form of Waiver Agreement (Filed With SEC on May 13, 2022)
- Form of Indemnification Agreement (Filed With SEC on May 5, 2022)
- Description of Capital Stock (Filed With SEC on March 31, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on March 1, 2022)
- Form of Series C Warrant (Filed With SEC on March 1, 2022)
- Form of Placement Agent Warrant (Filed With SEC on March 1, 2022)
- Form of Warrant Amendment Agreement (Filed With SEC on March 1, 2022)
- Form of Purchase Agreement (Filed With SEC on March 1, 2022)
- Employment Agreement by and between First Wave BioPharma, Inc. and Sarah Romano, dated February 14, 2022 (Filed With SEC on February 17, 2022)
- Form of Waiver (Filed With SEC on February 7, 2022)
- Settlement Agreement, by and between the Company and Fortis Advisors LLC, dated November 15, 2021 (Filed With SEC on November 16, 2021)
- Agreement and Plan of Merger, dated September 13, 2021, by and among the Company, Alpha Merger Sub, Inc., First Wave Bio, Inc. and Fortis Advisors LLC, as shareholders... (Filed With SEC on September 13, 2021)
- Amended and Restated Underwriting Agreement, dated July 22, 2021, between AzurRx BioPharma, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on July 27, 2021)
- Form of Wainwright Warrant (Filed With SEC on July 27, 2021)
- Form of Warrant (Filed With SEC on March 10, 2021)
- Form of Wainwright Warrant (Filed With SEC on March 10, 2021)
- License Agreement, dated December 31, 2020, by and between the Company and First Wave Bio, Inc (Filed With SEC on January 13, 2021)
- Form of Wainwright Warrant (Filed With SEC on January 8, 2021)
- Employment Agreement by and between AzurRx BioPharma, Inc. and Mr. Schneiderman, dated January 1, 2020 (Filed With SEC on January 6, 2020)
- Employment Agreement by and between AzurRx BioPharma, Inc. and James Sapirstein, dated October 8, 2019 (Filed With SEC on October 11, 2019)
- Underwriting Agreement, dated July 17, 2019 (Filed With SEC on July 22, 2019)
- Form of Wainwright Warrant (Filed With SEC on July 22, 2019)
- Form of Selling Agent Warrant (Filed With SEC on May 14, 2019)
- Selling Agent Agreement, by and between AzurRx BioPharma, Inc. and Alexander Capital, L.P., dated May 9, 2019 (Filed With SEC on May 14, 2019)
- Form of Selling Agent Warrant (Filed With SEC on April 3, 2019)
- Selling Agent Agreement, by and between AzurRx BioPharma, Inc. and Alexander Capital, L.P., dated April 1, 2019 (Filed With SEC on April 3, 2019)
- AssetPurchaseAgreement, by and betweenAzurRxBioPharma, Inc.,AzurRxBioPharmaSAS andLaboratoiresMayolySpindler SAS, dated March 27, 2019 (Filed With SEC on April 1, 2019)
- Patent License Agreement, by and betweenAzurRxBioPharma, Inc. andLaboratoiresMayolySpindler SAS, dated March 27, 2019 (Filed With SEC on April 1, 2019)
- Note Purchase Agreement, dated February 14, 2019 (Filed With SEC on February 20, 2019)
- Senior Convertible Note A, dated February 14, 2019 (Filed With SEC on February 20, 2019)
- Senior Convertible Note B, dated February 14, 2019 (Filed With SEC on February 20, 2019)
- Form of Pledge Agreement, dated February 14, 2019 (Filed With SEC on February 20, 2019)
- Warrant Amendment Agreement, dated February 14, 2019 (Filed With SEC on February 20, 2019)
- Registration Rights Agreement, dated February 14, 2019 (Filed With SEC on February 20, 2019)
- Asset Sale and Purchase Agreement, dated December 7, 2018, by and between Protea Biosciences Group, Inc., Protea Biosciences, Inc. and AzurRx Biopharma, Inc (Filed With SEC on December 13, 2018)
- Underwriting Agreement, dated May 1, 2018 (Filed With SEC on May 4, 2018)
- Form of Underwriter Warrant (Filed With SEC on May 4, 2018)
- Form of Exercise Letter (Filed With SEC on January 5, 2018)
- Form of Partial Exercise Letter (Filed With SEC on January 5, 2018)
- Modification to 12% Senior Secured Original Issue Discount Convertible Debenture, dated November 10, 2017 (Filed With SEC on November 13, 2017)
- Employment Agreement, by and between AzurRx BioPharma, Inc. and Maged Shenouda, dated September 26, 2017 (Filed With SEC on October 2, 2017)
- SUBLICENSE AGREEMENT (Filed With SEC on August 11, 2017)
- Form of Securities Purchase Agreement, dated June 5, 2017 (Filed With SEC on June 9, 2017)
- Form of Registration Rights Agreement, dated June 5, 2017 (Filed With SEC on June 9, 2017)
- Series A Warrant, dated June 5, 2017 (Filed With SEC on June 9, 2017)
- Series A-1 Warrant, dated June 5, 2017 (Filed With SEC on June 9, 2017)
- Securities Purchase Agreement, dated April 11, 2017 (Filed With SEC on April 12, 2017)
- 12% Senior Secured Original Issue Discount Convertible Debenture (Filed With SEC on April 12, 2017)
- Warrant, dated April 11, 2017 (Filed With SEC on April 12, 2017)
- Registration Statement, dated April 11, 2017 (Filed With SEC on April 12, 2017)
- UNDERWRITINGAGREEMENT among AZURRXBIOPHARMA, INC. and WALLACHBETHCapital, LLC and NETWORK 1 FINANCIAL SECURITIES, INC., asRepresentatives of the Several Underwriters (Filed With SEC on October 14, 2016)
- UNDERWRITINGAGREEMENT among AZURRXBIOPHARMA, INC. and WALLACHBETHCapital, LLC and NETWORK 1 FINANCIAL SECURITIES, INC., asRepresentatives of the Several Underwriters... (Filed With SEC on October 5, 2016)
- COMMON STOCK PURCHASE WARRANT For the Purchase of [] Shares of Common Stock of AZURRX BIOPHARMA, INC. (Filed With SEC on August 5, 2016)
- COMMON STOCK PURCHASE WARRANT For the Purchase of [] Shares of Common Stock of AZURRX BIOPHARMA, INC. (Filed With SEC on July 29, 2016)
- AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT AZURRX BIOPHARMA, INC. (Filed With SEC on July 13, 2016)
- STOCK PURCHASE AND SALE AGREEMENT DATED MAY 21, 2014 BY AND AMONG AZURRX BIOPHARMA, INC. AND PROTEA BIOSCIENCES GROUP, INC. AND PROTEA BIOSCIENCES, INC. AND PROTEABIO EUROPE SAS (Filed With SEC on July 13, 2016)
- AZURRX BIOPHARMA, INC. AMENDED AND RESTATED 2014 OMNIBUS EQUITY INCENTIVE PLAN (Filed With SEC on July 13, 2016)
- AZURRX BIOPHARMA, INC. EMPLOYMENT AGREEMENT (Filed With SEC on July 13, 2016)
